Evidence map›Paper›PMID 24361645›Full record

ArticleJournal of biomolecular screening2014

Phenotypic profiling of Raf inhibitors and mitochondrial toxicity in 3D tissue using biodynamic imaging.

Ran An, Dan Merrill, Larisa Avramova, Jennifer Sturgis, Maria Tsiper, J Paul Robinson, John Turek, David D Nolte

Abstract read
In one paragraph

Article in Journal of biomolecular screening, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Machine Learning with Optical Phase Signatures for Phenotypic Profiling of Cell Lines.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Predictive value ofConvergent science physical oncology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ran An1Purdue University, West Lafayette, IN, USA.
Dan Merrill
Larisa Avramova
Jennifer Sturgis
Maria Tsiper
J Paul Robinson
John Turek
David D Nolte

Funding

Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian CancerR01EB016582 · NIBIB · PURDUE UNIVERSITY · PI MATEI, DANIELA E, NOLTE, DAVID D · 2013 to 2016
$1.3M
NIBIB NIH HHS 1R01EB016582-01NIBIB NIH HHS R01 EB016582
6 · The paper itself

Abstract

The existence of phenotypic differences in the drug responses of 3D tissue relative to 2D cell culture is a concern in high-content drug screening. Biodynamic imaging is an emerging technology that probes 3D tissue using short-coherence dynamic light scattering to measure the intracellular motions inside tissues in their natural microenvironments. The information content of biodynamic imaging is displayed through tissue dynamics spectroscopy (TDS) but has not previously been correlated against morphological image analysis of 2D cell culture. In this article, a set of mitochondria-affecting compounds (FCCP, valinomycin, nicardipine, ionomycin) and Raf kinase inhibitors (PLX4032, PLX4720, GDC, and sorafenib) are applied to multicellular tumor spheroids from two colon adenocarcinoma cell lines (HT-29 and DLD-1). These were screened by TDS and then compared against conventional image-based high-content analysis (HCA). The responses to the Raf inhibitors PLX4032 and PLX4720 are grouped separately by cell line, reflecting the Braf/Kras difference in these cell lines. There is a correlation between TDS and HCA phenotypic clustering for most cases, which demonstrates the ability of dynamic measurements to capture phenotypic responses to drugs. However, there are significant 2D versus 3D phenotypic differences exhibited by several of the drugs/cell lines.

Indexed as

Drug Evaluation, PreclinicalCell Line, TumorCluster AnalysisDrug DiscoveryDrug Screening Assays, AntitumorHigh-Throughput Screening AssaysHumansMitochondriaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSpectrophotometrySpheroids, CellularTumor Cells, CulturedProtein Kinase InhibitorsProto-Oncogene Proteins B-rafcell-based assaysimaging technologieslabel-free technologiesphenotypic drug discovery

Identifiers

PMID24361645
PMCPMC4028716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.